Achieving a better cure for cancer

More info


CiMaas develops immunotherapy for cancer by optimally engaging the immune system.

Read more about CiMaas Immunotherapy products,
or watch our video.

News /

Combotope Therapeutics and CiMaas Announce Oncology Research and License Option Agreement

Collaboration for the discovery and development of innovative cancer-specific CAR-NK products is underway, leveraging Combotope Therapeutics' proprietary Tumor Glycoform specific scFv discovery platform and CiMaas's Adoptive CAR-NK technology.

  • CiMaas has the option to develop and commercialize up to three therapeutic candidates.
  • Combotope Therapeutics will receive upfront payment, success fees, and royalties on sales.
  • First candidate Mucin-1 tumor glycoform nominated.
News /

CiMaas has created a master cell and working cell bank of its feeder cell line to expand NK cells with maximum proliferation

CiMaas BV announces that it has created a GMP grade master cell bank of the F012 feeder cell line to support Natural Killer (NK) cell expansion isolated from peripheral blood cells. CiMaas had generated a feeder cell line containing two genes that induce NK cell proliferation and maturation resulting in NK cells with a memory phenotype and high killing capacity.